^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:cisplatin (DNA synthesis inhibitor) +
    Pemfexy (pemetrexed RTD) (Thymidylate synthase inhibitor, THF dehydrogenase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    02/08/2020
    Excerpt:
    PEMFEXY is a folate analog metabolic inhibitor indicated...in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non-squamous, non-small cell lung cancer (NSCLC).